Consensus Incyte Corporation

Stocks

INCY

US45337C1027

Pharmaceuticals

Real-time Estimate Cboe BZX 15:21:48 21/10/2026 BST			5-day change	1st Jan Change
115.58 ^USD	-0.89%		+3.34%	+16.74%

11:19am	TD Cowen Adjusts Price Target on Incyte to $140 From $138	MT
10-19	Incyte Insider Sold Shares Worth $297,780, According to a Recent SEC Filing	MT

Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

b.gJJaGcHixIcTAy0vZ01r7qc24eGQ1WLOp6LmuUdtxso.rfkxQaqwosZSRGhOFzgIpv1xh9HX5QT809SO835dg_np4h9Iq4WgtCJHRg~3fd73209943f78e01a88279d6c3d2f92

Analysts' recommendations: Incyte Corporation

11:19am	TD Cowen Adjusts Price Target on Incyte to $140 From $138	MT
10-15	Goldman Sachs Adjusts Price Target on Incyte to $117 From $118	MT
10-14	Truist Raises Price Target on Incyte to $115 From $105, Keeps Hold Rating	MT
10-08	RBC Lifts Price Target on Incyte to $114 From $109, Keeps Sector Perform Rating	MT
10-05	Stifel Adjusts Price Target on Incyte to $157 From $145, Keeps Buy Rating	MT
10-01	Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating	MT
09-28	HC Wainwright Adjusts Price Target on Incyte to $152 From $150, Maintains Buy Rating	MT
09-28	JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating	MT
08-20	Canaccord Genuity Initiates Incyte at Buy With $152 Price Target	MT
08-17	Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating	MT
08-13	Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating	MT
08-03	Mizuho Adjusts Price Target on Incyte to $137 From $121	MT
08-03	Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating	MT
07-31	Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating	MT
07-30	JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating	MT
07-29	Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says	MT
07-29	TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating	MT
07-29	Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating	MT
07-29	Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating	MT
07-29	BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating	MT
07-29	Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating	MT
07-29	Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating	MT
07-29	HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating	MT
07-29	Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating	MT
07-29	RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	INCYTE CORPORATION					+11.05%
	ELI LILLY AND COMPANY					+3.71%
	JOHNSON & JOHNSON					+7.73%
	ABBVIE INC.					-2.24%
	ROCHE HOLDING AG					-1.52%
	MERCK & CO., INC.					+6.92%
	NOVARTIS AG					-2.21%
	ASTRAZENECA PLC					+24.46%
	AMGEN INC.					-10.02%
	GILEAD SCIENCES, INC.					+2.33%
	Average					+4.02%
	Weighted average by Cap.					+3.47%